Antibiotic adjuvants: identification and clinical use by Bernal, P et al.
Highlight
Antibiotic adjuvants: identification and clinical use
Patricia Bernal, Carlos Molina-Santiago, Abdelali
Daddaoua and María A. Llamas*
Estación Experimental del Zaidín, Consejo Superior de
Investigaciones Científicas (CSIC), 18008 Granada,
Spain.
The discovery of penicillin by Alexander Fleming in 1928
changed the course of medicine. Since then, antibiotics
have represented virtually the only effective treatment
option for bacterial infections. However, their efficacy has
been seriously compromised by over-use and misuse of
these drugs, which have led to the emergence of bacteria
that are resistant to many commonly used antibiotics.
Bacteria present three general categories of antibiotic
resistance: acquired, intrinsic and adaptive (Alekshun and
Levy, 2007). Acquired resistance is the result of mutations
in chromosomal genes or the incorporation of new genetic
material (plasmids, transposons, integrons, naked DNA)
by horizontal gene transfer. It provides selective advan-
tage in the presence of antimicrobial compounds and it is
passed on to progeny resulting in the emergence of
antibiotic-resistant strains. Bacteria have an extraordinary
ability to acquire antibiotic resistance, which is best under-
stood from an evolutionary perspective. Thus, while the
use of antibiotics as therapeutics started less than 70
years ago, bacterial resistance mechanisms have
co-evolved with natural antimicrobial compounds for bil-
lions of years (D’Costa et al., 2011). Bacterial intrinsic
resistance to antibiotics is, in contrast to acquired resist-
ance, not related to antibiotic selection but to the specific
characteristics of the bacteria. Gram-negative bacteria
are for example resistant to many antibiotics due to the
presence of a lipopolysaccharide-containing outer mem-
brane with low permeability that functions as an extra
barrier preventing the entrance of antibiotics into the cell.
Furthermore, many bacteria contain efflux pumps that
pump antibiotics out of the cell and thereby decrease
their effectiveness. Finally, adaptive resistance involves a
temporary increase in the ability of a bacterium to survive
an antibiotic, mainly as the result of alterations in gene
and/or protein expression triggered by environmental con-
ditions (i.e. stress, nutrient conditions, growth state,
subinhibitory levels of the antibiotic) (Poole, 2012). In
contrast to intrinsic and acquired resistance mechanisms,
which are stable and can be transmitted on to the
progeny, adaptive resistance is transient and usually
reverts upon the removal of the inducing condition.
The combination of these antibiotic resistance mecha-
nisms has led to the emergence of multidrug-resistant
pathogens, which are a serious threat for medical care.
Among other strategies, the discovery or development of
new antibiotic agents had been thought to be a solution to
overcome the deficiencies of the existing ones. However,
development and marketing approval of new antibiotics
have not kept pace with the increasing public health threat
of bacterial drug resistance. An alternative to the devel-
opment of new antibiotics is to find potentiators of the
already existing ones, a less expensive alternative to the
problem (Ejim et al., 2011; Kalan and Wright, 2011).
Potentiators of antibiotic activity are known as antibiotic
adjuvants. These compounds are active molecules, pref-
erably with non-antibiotic activity, that in combination with
antibiotics enhance the antimicrobial activity of the latter.
Combinations of two antibiotics are also considered
adjuvants when their effect is synergistic (i.e. the co-
administration of the two drugs has a significantly
greater effect than that of each antibiotic alone). Antibiotic
adjuvants can function either by reversing resistance
mechanisms in naturally sensitive pathogens or by sensi-
tizing intrinsic resistant strains. Identification of new mol-
ecules that can function as adjuvants is currently an
important topic of research. In this context, Taylor and
colleagues have recently published a work aimed to iden-
tify molecules that potentiate the antimicrobial activity of
antibiotics commonly used against Gram-positive bacteria
but that have, however, little or no effect on Gram-
negative pathogens (Taylor et al., 2012). Using the
Gram-negative bacterium Escherichia coli as model in
combination with the aminocoumarin antibiotic novo-
biocin, the authors set up and performed a forward
chemical genetic screen with a library of 30 000 small
molecules. Three rounds of selection in which molecules
that did not enhance novobiocin activity, that had intrinsic
antibacterial activity, or that had undesirable secondary
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effects were discarded, identified four new compounds
that increase the antimicrobial activity of novobiocin and
other ‘Gram-positive’ antibiotics against E. coli. All identi-
fied molecules alter bacterial cell shape by blocking
cytoskeleton proteins (i.e. MerB) and/or peptidoglycan
biosynthesis, and act synergistically with the antibiotic.
Authors conclude that cell shape alterations likely disturb
the influx/efflux machinery of Gram-negative bacteria and
thereby enable the accumulation of otherwise excluded
antibiotics. This finding provides an attractive strategy
to combat the intrinsic antibiotic resistance of Gram-
negative bacteria and can aid the development of new
therapies that enhance the activity of existing antibiotics
against them.
The four compounds identified in this work potentiate
antibiotic activity by affecting a vital physiological bacterial
function, but potentiation of antibiotic activity can also
occur by: (i) inhibition of antibiotic resistance elements; (ii)
enhancement of the uptake of the antibiotic through the
bacterial membrane; (iii) direct blocking of efflux pumps;
and (iv) changing the physiology of resistant cells (i.e.
dispersal of biofilms to planktonic cells which are more
susceptible to antibiotics) (Kalan and Wright, 2011). Exam-
ples of currently used/identified antibiotic adjuvants are
given in Table 1. The most successful and clinically used
strategy to date has been the combination of a b-lactam
antibiotic with a b-lactamase inhibitor adjuvant. The
b-lactamase inhibitor enhances the action of the antibiotic
by inhibiting the function of the b-lactam degrading
enzyme b-lactamases. Thus, the adjuvant restores the
activity of the b-lactam antibiotic against b-lactamase-
producing pathogens. Three b-lactamase inhibitors have
already been registered: clavulanic acid, tazobactam and
sulbactam (Drawz and Bonomo, 2010) (Table 1). Clavu-
lanic acid is mainly given in combination with the antibiotic
amoxicillin, which has been commercialized as Augmen-
tin® (Brown et al., 1976). Although this antimicrobial
drug combination is on the market since 1981 and has
been extensively used, the emergence of resistance to
Augmentin in clinical isolates has been very low
(Leflon-Guibout et al., 2000), which is another important
advantage of pairing antibiotics with adjuvants. The strat-
egy of pairing an inhibitor of antibiotic degrading enzymes
with the antibiotic has also been applied against dehy-
dropeptidase, an enzyme that degrades the b-lactam anti-
biotic imipenem. The adjuvant cilastatin inhibits the action
of this enzyme and protects imipenem from degradation
prolonging its antibacterial effect when given in com-
bination (Balfour et al., 1996) (Table 1). Inhibitors for
aminoglycoside-modifying enzymes and erythromycin
ribosomal methylases have also been identified (Feder
et al., 2008; Vong et al., 2012), but none of them has been
considered sufficiently potent for further development as
antibiotic adjuvants. Another way of preventing antibiotic
degradation is by targeting the bacterial regulatory
systems involved in the expression of antibiotic resistance
genes. Bacteria respond to specific environmental signals,
such as presence of antibiotics, using signal transduction
mechanisms (i.e. two-component systems). Inhibition of
such regulatory systems is a promising strategy for the
development of antibiotic adjuvants (Lee et al., 2009;
Nguyen et al., 2010). Desirable candidates for antibiotic
adjuvants are also those molecules that enhance antibiotic
entrance into cells. Polymyxin E, also known as colistin, is
a cationic polypeptide antibiotic that interferes with the
LPS and permeabilizes the outer membrane of Gram-
negative bacteria. Clinical use for this antibiotic has been
limited due to toxicity concerns, but at lower concentra-
tions it has been used as adjuvant and enhances the
activity of the antibiotics rifampin and vancomycin against
Gram-negative pathogens (Aoki et al., 2009; Gordon
et al., 2010). Molecules that prevent antibiotics from being
pump out the bacterial cells are also desirable adjuvants.
Generally, there are several possibilities to achieve inhibi-
tion of bacterial efflux pumps (for review see Pagès and
Amaral, 2009). One of the most promising starting points is
the use of substrate analogues that compete with the
antibiotic for the pump since such analogues can be
rationally designed (Van Bambeke et al., 2010) (Table 1).
To date, a large number of efflux pump inhibitors have
been discovered and patented (Van Bambeke et al., 2010;
Bhardwaj and Mohanty, 2012). Although the process of
commercialization of these molecules is rather slow, efflux
pump inhibitors represents a promising strategy for antibi-
otic combination therapy. Furthermore, adjuvants can
enhance antibiotic potency by changing the physiology of
resistant cells. An example is by disrupting the bacterial
biofilm lifestyle, in which bacteria are more resistant to
antibiotic (Stewart and Costerton, 2001). Mixtures of
D-amino acids have been shown to disperse biofilm of
Gram-positive and Gram-negative bacteria (Kolodkin-Gal
et al., 2010). Moreover, the combination of antibiotic with
antibiofilm exopolysaccharides is also a promising strat-
egy to enhance the antimicrobial activity of common anti-
biotics, having the advantage that exopolysaccharides are
not toxic for human tissues (Bernal and Llamas, 2012;
Rendueles et al., 2013).
In conclusion, the use of antibiotic adjuvants has two
beneficial outcomes: enhancement of the antimicrobial
effect and reduction of the occurrence of mutations that
result in resistance. In this context, efforts to find such
molecules should be intensified. Since environmental
organisms are the source of most resistance genes and
antibiotics (D’Costa et al., 2006), screens of bacterial
natural products are likely to be productive in finding mol-
ecules that inhibit antibiotic resistance elements, as
proven by the discovery of clavulanic acid (Brown et al.,
1976). Additionally, a screen of a library of plant-derived
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compounds has also identified potentiators of antibiotics
(Chusri et al., 2009), mainly through efflux pump inhibi-
tion. Although still poorly explored, inhibition of regulatory
mechanisms that control bacterial virulence functions
represents a promising strategy for antibiotic adjuvant
therapy. The non-essential character of these functions
may significantly reduce the development of resistance.
The continuous advances in the development of new and
potent high-throughput technologies will definitively allow
the discovery of new compounds with antibiotic adjuvant
activity.
Conflict of interest
None declared.
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